journal
MENU ▼
Read by QxMD icon Read
search

Diabetes Technology & Therapeutics

journal
https://www.readbyqxmd.com/read/28891680/expanding-treatment-options-for-improving-health-outcomes-in-type-1-diabetes
#1
Satish K Garg
No abstract text is available yet for this article.
September 11, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28854339/improving-the-safety-and-functionality-of-an-artificial-pancreas-system-for-use-in-younger-children-input-from-parents-and-physicians
#2
Rachel Gildersleeve, Sara L Riggs, Daniel R Cherñavvsky, Marc D Breton, Mark D DeBoer
BACKGROUND: Artificial pancreas (AP) systems have initially been designed for and tested in teens and adults, but there is evidence that an AP system with additional support and safety systems could greatly benefit younger children with type 1 diabetes (T1D). SUBJECTS AND METHODS: Five pediatric endocrinologists and 15 parents of children aged 5-8 years with T1D participated in a total of four focus groups. Focus groups investigated current diabetes technology use and acceptance, as well as possible modifications to the current adult AP system, which would allow for safe and successful use in younger children...
August 30, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28846447/stability-of-commercially-available-glucagon-formulation-for-dual-hormone-artificial-pancreas-clinical-use
#3
Nadine Taleb, Adèle Coriati, Christian Khazzaka, Jonathan Bayonne, Virginie Messier, Rémi Rabasa-Lhoret
BACKGROUND: Available glucagon formulations are approved for immediate use after reconstitution for severe hypoglycemia emergency treatment. However, they are used in dual-hormone artificial pancreas (insulin and glucagon) studies through subcutaneous infusion pumps over 24 h. Chemical and physical stability of such glucagon use have not been reported in a comprehensive manner. MATERIALS AND METHODS: Recombinant Glucagon DNA (Eli Lilly) was used. Compatibility and sterility of glucagon delivery through subcutaneous pump systems were verified...
August 28, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28836833/continuous-glucose-monitoring-in-patients-with-type-1-diabetes-and-impaired-awareness-of-hypoglycemia-also-effective-in-patients-with-psychological-distress
#4
Cornelis A J van Beers, Maartje de Wit, Susanne J Kleijer, Petronella H Geelhoed-Duijvestijn, J Hans DeVries, Mark H H Kramer, Michaela Diamant, Erik H Serné, Frank J Snoek
The aim of this study was to evaluate whether psychological distress modifies the effect of continuous glucose monitoring (CGM) in patients with type 1 diabetes (T1D) and impaired awareness of hypoglycemia. Fifty-two patients with T1D and impaired awareness of hypoglycemia participated in an earlier reported randomized crossover trial with two 16-week intervention periods comparing CGM with self-monitoring of blood glucose (SMBG). During the CGM phase, time spent in euglycemia (4-10 mmol/L), the primary outcome, was 9...
August 24, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28832184/type-1-diabetes-at-high-altitude-performance-of-personal-insulin-pumps-and-patient-metabolic-control
#5
Bartłomiej Matejko, Andrzej Gawrecki, Marta Wróbel, Jerzy Hohendorff, Teresa Benbenek-Klupa, Maciej T Malecki, Dorota Zozulińska-Ziółkiewicz, Tomasz Klupa
High-altitude trekking can expose people to extreme environmental conditions, like low temperatures and hypobaric hypoxia. Such extreme conditions make it more difficult for people with type 1 diabetes mellitus (T1DM) to maintain glycemic control. Intensive blood glucose monitoring using either glucose meters or continuous systems is imperative in these cases. In this observational study, we report metabolic control of T1DM patients and the performance of various insulin pumps at high altitude. All 19 patients with T1DM included in this study participated in the final step of the "5000 meters above sugar level" initiative, which involved trekking Damavand Mountain to an altitude of 5670 meters above sea level...
August 23, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28829163/effect-of-dapagliflozin-on-glycemic-control-weight-and-blood-pressure-in-patients-with-type-2-diabetes-attending-a-specialist-endocrinology-practice-in-canada-a-retrospective-cohort-analysis
#6
Ruth E Brown, Nikhil Gupta, Ronnie Aronson
BACKGROUND: In randomized clinical trials, dapagliflozin has been shown to improve glycemic control, weight, and blood pressure. However, there is little real-world evidence of the effectiveness of dapagliflozin. The objective of this study is to investigate the real-world treatment outcomes of patients with type 2 diabetes (T2D) who initiated dapagliflozin in a referral-based endocrinology practice. METHODS: This study was a retrospective cohort analysis of patients with T2D who initiated dapagliflozin in 2015, using data from a large, specialist diabetes registry in Canada...
August 22, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28829160/venous-arterialized-venous-or-capillary-glucose-reference-measurements-for-the-accuracy-assessment-of-a-continuous-glucose-monitoring-system
#7
Jort Kropff, Sigrid C van Steen, Peter deGraaff, Man W Chan, Rombout B E van Amstel, J Hans DeVries
BACKGROUND: Different reference methods are used for the accuracy assessment of continuous glucose monitoring (CGM) systems. The effect of using venous, arterialized-venous, or capillary reference measurements on CGM accuracy is unclear. METHODS: We evaluated 21 individuals with type 1 diabetes using a capillary calibrated CGM system. Venous or arterialized-venous reference glucose samples were taken every 15 min at two separate visits and assessed per YSI 2300 STAT Plus...
August 22, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28704063/evaluation-of-accuracy-of-six-blood-glucose-monitoring-systems-and-modeling-of-possibly-related-insulin-dosing-errors
#8
Annette Baumstark, Nina Jendrike, Stefan Pleus, Cornelia Haug, Guido Freckmann
OBJECTIVE: Self-monitoring of blood glucose (BG) is an essential part of diabetes therapy. Accurate and reliable results from BG monitoring systems (BGMS) are important especially when they are used to calculate insulin doses. This study aimed at assessing system accuracy of BGMS and possibly related insulin dosing errors. RESEARCH DESIGN AND METHODS: System accuracy of six different BGMS (Accu-Chek(®) Aviva Nano, Accu-Chek Mobile, Accu-Chek Performa Nano, CONTOUR(®) NEXT LINK 2...
July 13, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28704062/flextouch-an-insulin-pen-injector-with-a-low-activation-force-across-different-insulin-formulations-needle-technologies-and-temperature-conditions
#9
Niels Gudiksen, Thibaud Hofstätter, Birgitte B Rønn, Thomas Sparre
FlexTouch® (Novo Nordisk A/S, Bagsvaerd, Denmark) is a pen-injector with a torque spring mechanism requiring a low activation force. This laboratory-based study compared the activation force of FlexTouch during the injection of insulin with different needles and at temperature conditions within the range at which the device is recommended for use. Using a tensile tester, activation force was measured at maximum dose settings for insulin detemir (100 U/mL) and insulin degludec (100 and 200 U/mL) at standard (23°C ± 5°C), cool (5°C ± 3°C), and warm (30°C ± 2°C) conditions...
July 13, 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28930495/a-multicenter-real-life-study-on-the-effect-of-flash-glucose-monitoring-on-glycemic-control-in-patients-with-type-1-and-type-2-diabetes
#10
Ranjit Mohan Anjana, Jothydev Kesavadev, Deshpande Neeta, Mangesh Tiwaskar, Rajendra Pradeepa, Saravanan Jebarani, Suresh Thangamani, Nadiminty Ganapathi Sastry, Srivastava Brijendra Kumar, Muthu Ramu, Pokal Prasanna Kumar Gupta, Jayaprakash Vignesh, Sundramoorthy Chandru, Sengottuvel Kayalvizhi, Padoor Sethuraman Jagdish, Subash Chandra Bose Uthra, Munawar Lovelena, Sah Jyoti, Sengodan Suguna Priya, Alagarsamy Kannan, Viswanathan Mohan, Ranjit Unnikrishnan
AIM: To assess the efficacy of ambulatory glucose profiling (AGP) generated by FreeStyle LibrePro(™) flash glucose monitoring (FCGM) on glycemic control in patients with uncontrolled type 1 diabetes (T1D) and type 2 diabetes (T2D). METHODS: Clinical and biochemical data were obtained from 5072 patients with diabetes who had an A1c ≥7% (2536 who had been initiated on FCGM-based AGP between March 2015 and October 2016 [cases] and 2536 age-, gender-, A1c-, site- and time-matched controls who were not initiated on AGP) across seven diabetes clinics in India...
September 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28885037/will-biosimilar-insulins-be-cheaper
#11
Lutz Heinemann, Alan W Carter
No abstract text is available yet for this article.
September 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28771387/minimizing-glycemic-fluctuations-in-patients-with-type-2-diabetes-approaches-and-importance
#12
Paresh Dandona
Glycemic fluctuations, characterized by short-term oscillations in plasma glucose, are important when managing type 2 diabetes (T2D) and may be considered a target of glucose-lowering therapies. Continuous glucose monitoring (CGM) has been used to evaluate the effects of different treatments on glycemic fluctuations. This review examines approaches to and the importance of minimizing glycemic fluctuations among patients with T2D. Measures of HbA1c, fructosamine, and glycated albumin reflect a long-term average of plasma glucose, and are therefore unable to provide an accurate measure of short-term glycemic oscillations...
September 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28767276/closed-loop-control-without-meal-announcement-in-type-1-diabetes
#13
Faye M Cameron, Trang T Ly, Bruce A Buckingham, David M Maahs, Gregory P Forlenza, Carol J Levy, David Lam, Paula Clinton, Laurel H Messer, Emily Westfall, Camilla Levister, Yan Yan Xie, Nihat Baysal, Daniel Howsmon, Stephen D Patek, B Wayne Bequette
OBJECTIVE: A fully closed-loop insulin-only system was developed to provide glucose control in patients with type 1 diabetes without requiring announcement of meals or activity. Our goal was to assess initial safety and efficacy of this system. RESEARCH DESIGN AND METHODS: The multiple model probabilistic controller (MMPPC) anticipates meals when the patient is awake. The controller used the subject's basal rates and total daily insulin dose for initialization. The system was tested at two sites on 10 patients in a 30-h inpatient study, followed by 15 subjects at three sites in a 54-h supervised hotel study, where the controller was challenged by exercise and unannounced meals...
September 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28749169/effects-of-sodium-glucose-cotransporter-2-inhibitors-on-serum-uric-acid-in-type-2-diabetes-mellitus
#14
Hala Ahmadieh, Sami Azar
Hyperuricemia has been linked to metabolic syndrome, cardiovascular disease, and chronic kidney disease. Hyperuricemia and type 2 diabetes mellitus were inter-related, type 2 diabetes mellitus was more at risk of having a higher serum uric acid level, and also individuals with higher serum uric acid had higher risk of developing type 2 diabetes in the future. Insulin resistance seems to play an important role in the causal relationship between metabolic syndrome, type 2 diabetes, and hyperuricemia. Oral diabetic drugs that would have additional beneficial effects on reducing serum uric acid levels are of importance...
September 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28722480/efficacy-and-safety-of-biosimilar-sar342434-insulin-lispro-in-adults-with-type-1-diabetes-also-using-insulin-glargine-sorella-1-study
#15
Satish K Garg, Karin Wernicke-Panten, Maria Rojeski, Suzanne Pierre, Yvonne Kirchhein, Krystyna Jedynasty
BACKGROUND: SAR342434 is a biosimilar follow-on of insulin lispro-Humalog(®). This study aimed to show similar efficacy, safety, and immunogenicity of SAR342434 (SAR-Lis) versus insulin lispro-Humalog (Ly-Lis) in adult patients with type 1 diabetes (T1DM) treated with multiple daily injections while using basal insulin glargine (Lantus(®); GLA-100). MATERIALS AND METHODS: SORELLA-1 was a randomized, open-label phase 3 study (NCT02273180). Patients completing the 6-month main study continued on SAR-Lis or Ly-Lis, as randomized, for a 6-month safety extension...
September 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28665142/targeting-one-hour-postmeal-glucose-is-it-time-for-a-paradigm-switch-in-diabetes-management
#16
Antonio Ceriello
In the management of diabetes, postprandial glycemia (PPG) is usually targeted 2 h after the start of meal. Recent evidences, however, suggest that the value of glycemia at 1 h during an oral glucose tolerance test (OGTT) is a stronger predictor for developing diabetes than the value at 2 h and that it is an independent risk factor for cardiovascular disease. Studies in cells, animals, and humans suggest that 1-h high glucose is a sufficient stimulus for increasing several cardiovascular risk factors, such as inflammation, thrombosis, and endothelial dysfunction, with oxidative stress generation as the possible pathogenetic factor...
September 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28817342/hypoglycemia-risk-related-to-double-dose-is-markedly-reduced-with-basal-insulin-peglispro-versus-insulin-glargine-in-patients-with-type-2-diabetes-mellitus-in-a-randomized-trial-imagine-8
#17
Cynthia Harris, Thomas Forst, Tim Heise, Leona Plum-Mörschel, Elaine Watkins, Qianyi Zhang, Ludi Fan, Parag Garhyan, Niels Porksen
BACKGROUND: Basal insulin peglispro (BIL) has a peripheral-to-hepatic distribution of action that resembles endogenous insulin and a prolonged duration of action with a flat pharmacokinetic/pharmacodynamic profile at steady state, characteristics that tend to reduce hypoglycemia risk compared to insulin glargine (GL). The primary objective was to demonstrate that clinically significant hypoglycemia (blood glucose ≤54 mg/dL [3.0 mmol/L] or symptoms of severe hypoglycemia) occurred less frequently within 84 h after a double dose (DD) of BIL than a DD of GL...
August 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28817341/assessment-of-interday-glucose-variability-in-type-2-diabetes
#18
Vikash Dadlani, Yogish C Kudva
No abstract text is available yet for this article.
August 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28767273/advances-in-subcutaneous-glucose-sensing
#19
Jessica R Castle
No abstract text is available yet for this article.
August 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28700272/accuracy-of-a-fourth-generation-subcutaneous-continuous-glucose-sensor
#20
Mark P Christiansen, Satish K Garg, Ronald Brazg, Bruce W Bode, Timothy S Bailey, Robert H Slover, Ashley Sullivan, Suiying Huang, John Shin, Scott W Lee, Francine R Kaufman
BACKGROUND: This study evaluated the accuracy and performance of a fourth-generation subcutaneous glucose sensor (Guardian(™) Sensor 3) in the abdomen and arm. METHODS: Eighty-eight subjects (14-75 years of age, mean ± standard deviation [SD] of 42.0 ± 19.1 years) with type 1 or type 2 diabetes participated in the study. Subjects wore two sensors in the abdomen that were paired with either a MiniMed(™) 640G insulin pump, or an iPhone(®) or iPod(®) touch(®) running a glucose monitoring mobile application (Guardian Connect system) and a third sensor in the arm, which was connected to a glucose sensor recorder (GSR)...
August 2017: Diabetes Technology & Therapeutics
journal
journal
34712
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"